Dr. Reddy’s announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Hyderabad, India, October 28, 2014
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE® (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
The RAPAMUNE® tablets brand had U.S. sales of approximately $206 Million MAT for the most recent twelve months ending in August 2014 according to IMS Health*.
Dr. Reddy’s Sirolimus tablets in 1 mg and 2 mg are available in bottle counts of 100.
BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
Warnings and Precautions
- Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression
- Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions .
- The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended [see Warnings and Precautions.
- Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT)
The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss in a study in de novo liver transplant patients. Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred within 30 days post- transplantation and most led to graft loss or death.
- Lung Transplantation - Bronchial Anastomotic Dehiscence
Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen [see Warnings and Precautions]
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com
RAPAMUNE® is a registered trademark of WYETH LLC LIMITED LIABILITY COMPANY
*IMS National Sales Perspectives: Retail and Non-Retail MAT August 2014
For more information please contact:
Investors and Financial Analysts:
Kedar Upadhye at firstname.lastname@example.org / +91-40-66834297
Saunak Savla at email@example.com / +91-40-49002135
Ashish Girotra (USA) at firstname.lastname@example.org / +1 609-375-9805
Shilpi Lathia at email@example.com / +91-40-49002448